Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases

Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases

BackgroundBrain metastases (BM), including brain parenchyma metastases (BPM) and leptomeningeal metastases (LM), are devastating metastatic complications in advanced cancer patients. Next-generation sequencing (NGS) is emerging as a new promising tool for profiling cancer mutation, which could facil...

Full description

Bibliographic Details
Main Authors:	Xiaocui Liu, Fengjun Mei, Mei Fang, Yaqiong Jia, Yazhu Zhou, Chenxi Li, Panpan Tian, Chufan Lu, Guangrui Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Oncology
Subjects:	non-small cell lung cancer (NSCLC) leptomeningeal metastases (LM) brain parenchyma metastases (BPM) cerebrospinal fluid circulating tumour DNA (ctDNA) next generation sequencing
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1322635/full

Similar Items

The Role of ctDNA in Gastric Cancer
by: Justin Mencel, et al.
Published: (2022-10-01)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
by: Josep Gumà, et al.
Published: (2022-11-01)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
by: Yan Li, et al.
Published: (2021-04-01)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01)

Role of ctDNA in Breast Cancer
by: Marta Sant, et al.
Published: (2022-01-01)

The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review
by: Agnieszka Kopystecka, et al.
Published: (2023-05-01)

CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report
by: Wen-Tsung Huang, et al.
Published: (2018-02-01)

Liquid Biopsy, ctDNA Diagnosis through NGS
by: Chen Lin, et al.
Published: (2021-08-01)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
by: Ibone Labiano, et al.
Published: (2023-02-01)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
by: Estela Sánchez-Herrero, et al.
Published: (2022-07-01)

How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks
by: Estelle Bourbon, et al.
Published: (2021-06-01)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
by: Wenwen Wang, et al.
Published: (2023-09-01)

Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
by: Rugile Pikturniene, et al.
Published: (2024-03-01)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
by: Yi-Ze Li, et al.
Published: (2023-02-01)

Quantitative ctDNA Detection in Hepatoblastoma: Implications for Precision Medicine
by: Smadar Kahana-Edwin, et al.
Published: (2023-12-01)

Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
by: Xin Chen, et al.
Published: (2023-05-01)

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy
by: Xiaoling Wang, et al.
Published: (2024-01-01)

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
by: Aakash Desai, et al.
Published: (2024-02-01)

Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management
by: Britney Niemann, et al.
Published: (2024-03-01)

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
by: Xiaohong Han, et al.
Published: (2019-10-01)

ctDNA Detection Based on DNA Clutch Probes and Strand Exchange Mechanism
by: Huan Chang, et al.
Published: (2018-10-01)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
by: Guangrui Li, et al.
Published: (2023-10-01)

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker
by: Li Li, et al.
Published: (2023-12-01)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
by: Edina Dizdarevic, et al.
Published: (2022-04-01)

Target Recognition– and HCR Amplification–Induced In Situ Electrochemical Signal Probe Synthesis Strategy for Trace ctDNA Analysis
by: Aiting Cai, et al.
Published: (2022-11-01)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
by: Joanne Chiu, et al.
Published: (2023-08-01)

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
by: Michael J. Duffy, et al.
Published: (2022-01-01)

Near-Infrared Light Regulation of Capture and Release of ctDNA Platforms Based on the DNA Assembly System
by: Chaihong Gong, et al.
Published: (2022-06-01)

ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
by: Ariana Huebner, et al.
Published: (2023-04-01)

Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma
by: Taehee Kim, et al.
Published: (2019-12-01)

Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
by: Fulong Wang, et al.
Published: (2023-12-01)

Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults
by: Jianfeng Liang, et al.
Published: (2020-08-01)

ACEK Biosensor for the Minute-Scale Quantification of Breast Cancer ctDNA
by: Ke Wang, et al.
Published: (2024-01-01)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
by: Jiayan Wei, et al.
Published: (2021-10-01)

Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment
by: Michael E. Egger, et al.
Published: (2024-04-01)

Basic ctDNA Panel Promises Affordable Clinical Validity in Colon Cancer Patients but Not in Pancreas Cancer Patients
by: Mandy Radefeldt, et al.
Published: (2023-11-01)

The Use of ctDNA for <i>BRAF</i> Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
by: Paweł Sobczuk, et al.
Published: (2022-02-01)

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice
by: Angela Lamarca, et al.
Published: (2022-02-01)

Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas
by: David Braig, et al.
Published: (2022-09-01)

The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues
by: Nong Yang, et al.
Published: (2018-03-01)